WO2018102594A8 - Methods of treating solid tumors with anti-cd200 antibodies - Google Patents

Methods of treating solid tumors with anti-cd200 antibodies Download PDF

Info

Publication number
WO2018102594A8
WO2018102594A8 PCT/US2017/064033 US2017064033W WO2018102594A8 WO 2018102594 A8 WO2018102594 A8 WO 2018102594A8 US 2017064033 W US2017064033 W US 2017064033W WO 2018102594 A8 WO2018102594 A8 WO 2018102594A8
Authority
WO
WIPO (PCT)
Prior art keywords
solid tumors
antibodies
methods
treating solid
treating
Prior art date
Application number
PCT/US2017/064033
Other languages
French (fr)
Other versions
WO2018102594A1 (en
Inventor
Xiaoping Zhang
Wei-jian PAN
Original Assignee
Alexion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals, Inc. filed Critical Alexion Pharmaceuticals, Inc.
Publication of WO2018102594A1 publication Critical patent/WO2018102594A1/en
Publication of WO2018102594A8 publication Critical patent/WO2018102594A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Abstract

The present disclosure provides methods for treating solid tumors using an effective amount of an anti-CD200 antibody, or antigen-binding fragment thereof.
PCT/US2017/064033 2016-12-01 2017-11-30 Methods of treating solid tumors with anti-cd200 antibodies WO2018102594A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662428838P 2016-12-01 2016-12-01
US62/428,838 2016-12-01
US201762466224P 2017-03-02 2017-03-02
US62/466,224 2017-03-02

Publications (2)

Publication Number Publication Date
WO2018102594A1 WO2018102594A1 (en) 2018-06-07
WO2018102594A8 true WO2018102594A8 (en) 2018-07-26

Family

ID=61022406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/064033 WO2018102594A1 (en) 2016-12-01 2017-11-30 Methods of treating solid tumors with anti-cd200 antibodies

Country Status (1)

Country Link
WO (1) WO2018102594A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019126133A1 (en) * 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3852304T3 (en) 1987-03-02 1999-07-01 Enzon Lab Inc Organism as carrier for "Single Chain Antibody Domain (SCAD)".
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
DE69233697T2 (en) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Process for the development of binding microproteins
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
RU2270030C2 (en) 1996-02-09 2006-02-20 Абботт Байотекнолоджи эЛтиди. METHOD AND OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT FOR INHIBITING HUMAN TNFα ACTIVITY, APPLYING THE OBTAINED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT AS INGREDIENT FOR PRODUCING MEDICAMENT
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
KR20140091765A (en) 2006-01-12 2014-07-22 알렉시온 파마슈티칼스, 인코포레이티드 Antibodies to ox-2/cd200 and uses thereof
BRPI0814644A2 (en) * 2007-07-25 2015-01-27 Alexion Pharma Inc CD200 ANTIBODIES AND USES OF THESE INHIBITING IMMUNE ANSWERS.
AU2011203879A1 (en) 2010-01-11 2012-08-02 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
NZ601580A (en) * 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
CA2826453A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts

Also Published As

Publication number Publication date
WO2018102594A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
WO2016062722A8 (en) Combination
WO2017152085A8 (en) Combination therapy with anti-cd73 antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2018093821A8 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
WO2017218707A3 (en) Bispecific checkpoint inhibitor antibodies
WO2016191643A3 (en) Tigit-binding agents and uses thereof
MX2018006973A (en) Humanized anti-cd73 antibodies.
EA201890302A1 (en) CHEMICAL ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF THEIR APPLICATION
EA201790339A1 (en) COMBINED DRUGS WITH ANTIBODIES TO CD40
WO2016014688A3 (en) Anti-pd-1 antibodies
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
SG10201901057UA (en) Anti-pd-l1 antibodies
WO2015091853A3 (en) Human anti-cd40 human antibodies
WO2018031490A3 (en) Anti-ox40 binding proteins
PH12016501366A1 (en) Novel anti-baff antibodies
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2017136659A3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
MX2022014695A (en) Anti-gitr antibodies and uses thereof.
EP3752180A4 (en) Methods for treating cancer with anti-pd-1 antibodies
WO2015010100A3 (en) Humanized antibodies with ultralong complementarity determining regions
CN106456764A8 (en) PDL 1 and PD 1 antagonist for treating HPV negative cancers
EP3487518A4 (en) HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
MY189618A (en) Antibody specifically binding to pd-1 and functional fragment thereof
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17833032

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17833032

Country of ref document: EP

Kind code of ref document: A1